Multivariable logistic regression analysis with DAS remission at year 1, ACR/EULAR (Boolean) remission at year 1 and drug-free DAS remission at year 5 as binomial outcome variable
| Multivariable logistic regression | DAS remission at year 1 | ACR/EULAR (Boolean) remission at year 1 | Drug-free DAS remission at year 5 | ||||||
| OR | 95% CI | P values | OR | 95% CI | P values | OR | 95% CI | P values | |
| DAS <1.6 steered study | 2.76 | 1.52 to 5.00 | 0.001 | 2.60 | 1.29 to 5.25 | 0.008 | 4.50 | 1.84 to 11.03 | 0.001 |
| Male gender | 2.40 | 1.30 to 4.42 | 0.005 | 1.87 | 0.97 to 3.61 | 0.061 | |||
| Symptom duration | 0.99 | 0.98 to 1.00 | 0.075 | 1.00 | 0.99 to 1.01 | 0.614 | 0.98 | 0.97 to 1.00 | 0.065 |
| Baseline DAS | 0.74 | 0.52 to 1.05 | 0.090 | 1.01 | 0.67 to 1.52 | 0.958 | 0.94 | 0.58 to 1.53 | 0.792 |
| Total SHS | 1.06 | 0.98 to 1.15 | 0.159 | 1.00 | 0.89 to 1.11 | 0.924 | 0.94 | 0.83 to 1.07 | 0.350 |
| Time on anti-TNF inhibitor | 0.95 | 0.93 to 0.98 | 0.001 | 0.94 | 0.90 to 0.98 | 0.006 | 0.91 | 0.86 to 0.97 | 0.002 |
| RF positive | 1.01 | 0.67 to 1.52 | 0.958 | ||||||
ACPA, anticitrullinated protein antibodies; ACR, American College of Rheumatology; anti-TNF, antitumour necrosis factor; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SHS, Sharp/van der Heijde Score; VAS, visual analogue scale.